DE69614057D1 - Selektive Beta3-adrenergische Agonisten - Google Patents
Selektive Beta3-adrenergische AgonistenInfo
- Publication number
- DE69614057D1 DE69614057D1 DE69614057T DE69614057T DE69614057D1 DE 69614057 D1 DE69614057 D1 DE 69614057D1 DE 69614057 T DE69614057 T DE 69614057T DE 69614057 T DE69614057 T DE 69614057T DE 69614057 D1 DE69614057 D1 DE 69614057D1
- Authority
- DE
- Germany
- Prior art keywords
- adrenergic agonists
- diabetes
- type
- selective
- beta3 adrenergic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- C07D213/643—2-Phenoxypyridines; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
- C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
- C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US408395P | 1995-09-21 | 1995-09-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69614057D1 true DE69614057D1 (de) | 2001-08-30 |
DE69614057T2 DE69614057T2 (de) | 2002-03-14 |
Family
ID=21709054
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69614057T Expired - Fee Related DE69614057T2 (de) | 1995-09-21 | 1996-09-20 | Selektive Beta3-adrenergische Agonisten |
Country Status (23)
Country | Link |
---|---|
EP (1) | EP0764632B1 (de) |
JP (1) | JPH11513376A (de) |
KR (1) | KR19990045727A (de) |
CN (1) | CN1202106A (de) |
AT (1) | ATE203511T1 (de) |
AU (1) | AU715493B2 (de) |
BR (1) | BR9610481A (de) |
CA (1) | CA2232090A1 (de) |
CZ (1) | CZ82198A3 (de) |
DE (1) | DE69614057T2 (de) |
DK (1) | DK0764632T3 (de) |
EA (1) | EA001217B1 (de) |
ES (1) | ES2158996T3 (de) |
GR (1) | GR3036963T3 (de) |
HU (1) | HUP9802257A3 (de) |
IL (1) | IL123677A0 (de) |
NO (1) | NO981204L (de) |
NZ (1) | NZ318712A (de) |
PL (1) | PL325865A1 (de) |
PT (1) | PT764632E (de) |
SI (1) | SI0764632T1 (de) |
TR (1) | TR199800521T1 (de) |
WO (1) | WO1997010822A1 (de) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5958957A (en) * | 1996-04-19 | 1999-09-28 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
AU2381397A (en) * | 1996-04-19 | 1997-11-12 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
CA2312849A1 (en) | 1997-12-05 | 1999-06-17 | Charles David Jones | Selective .beta.3 adrenergic agonists |
PE20000415A1 (es) | 1998-04-08 | 2000-05-21 | Smithkline Beecham Corp | Compuestos calciliticos |
AUPP796798A0 (en) * | 1998-12-30 | 1999-01-28 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
WO2001035947A2 (en) * | 1999-11-15 | 2001-05-25 | Eli Lilly And Company | Treating wasting syndromes with aryloxy propanolamines |
WO2001036412A1 (en) * | 1999-11-15 | 2001-05-25 | Eli Lilly And Company | Process for the preparation of aryloxy propanolamines |
FR2809725B1 (fr) * | 2000-06-06 | 2004-05-07 | Sanofi Synthelabo | Propanolaminotetralines, leur preparation et compositions pharmaceutiques en contenant |
FR2817257B1 (fr) * | 2000-11-30 | 2009-03-20 | Sanofi Synthelabo | Cyclohexyl(alkyl)-propanolamines, leur preparation et compositions pharmaceutiques en contenant |
AU2003209527A1 (en) | 2002-02-27 | 2003-09-09 | Pfizer Products Inc. | Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol |
US6864268B2 (en) | 2002-02-27 | 2005-03-08 | Pfizer Inc. | β3 adrenergic receptor agonists |
MXPA04008298A (es) | 2002-02-27 | 2004-11-26 | Pfizer Prod Inc | Procesos e intermedios utiles en la preparacion de agonistas de receptor beta-3 adrenergico. |
ES2394349B1 (es) | 2012-08-29 | 2013-11-04 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii | Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar |
WO2016210292A1 (en) | 2015-06-25 | 2016-12-29 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance |
JP7080179B2 (ja) | 2016-03-15 | 2022-06-03 | ザ チルドレンズ メディカル センター コーポレーション | 造血幹細胞の増大に関する方法および組成物 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3498999A (en) * | 1966-04-20 | 1970-03-03 | Bristol Myers Co | 1-phenoxy and substituted phenoxy-3-(5-tetrazolyl) propanes |
GB1433920A (en) * | 1973-10-01 | 1976-04-28 | Ici Ltd | Alkanolamine derivatives |
US4080471A (en) * | 1976-06-25 | 1978-03-21 | Aktiebolaget Hassle | Use of substituted isopropylaminopropanols for inducing inotropic effects of the human heart |
FR2640969B1 (de) * | 1988-12-23 | 1991-11-22 | Midy Spa | |
US5451677A (en) * | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
EP0627407A1 (de) * | 1993-05-28 | 1994-12-07 | MIDY S.p.A. | (7S)-7-(2R)-2(3-Chlorophenyl)-2-hydroxethylamino-5,6,7,8-Tetrahydronaphthalen-2-yloxy-Essigsäure, ihre pharmazeutisch akzeptablen Salze, mit Beta-3-adrenergischer agonistischer Aktivität und diese enthaltende pharmazeutische Zusammensetzung |
US5776983A (en) * | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
-
1996
- 1996-09-20 BR BR9610481A patent/BR9610481A/pt not_active Application Discontinuation
- 1996-09-20 HU HU9802257A patent/HUP9802257A3/hu unknown
- 1996-09-20 CN CN96198229A patent/CN1202106A/zh active Pending
- 1996-09-20 EP EP96306850A patent/EP0764632B1/de not_active Expired - Lifetime
- 1996-09-20 PL PL96325865A patent/PL325865A1/xx unknown
- 1996-09-20 AU AU70770/96A patent/AU715493B2/en not_active Ceased
- 1996-09-20 TR TR1998/00521T patent/TR199800521T1/xx unknown
- 1996-09-20 WO PCT/US1996/015103 patent/WO1997010822A1/en not_active Application Discontinuation
- 1996-09-20 JP JP9512920A patent/JPH11513376A/ja active Pending
- 1996-09-20 CZ CZ98821A patent/CZ82198A3/cs unknown
- 1996-09-20 CA CA002232090A patent/CA2232090A1/en not_active Abandoned
- 1996-09-20 DE DE69614057T patent/DE69614057T2/de not_active Expired - Fee Related
- 1996-09-20 DK DK96306850T patent/DK0764632T3/da active
- 1996-09-20 AT AT96306850T patent/ATE203511T1/de not_active IP Right Cessation
- 1996-09-20 ES ES96306850T patent/ES2158996T3/es not_active Expired - Lifetime
- 1996-09-20 IL IL12367796A patent/IL123677A0/xx unknown
- 1996-09-20 EA EA199800317A patent/EA001217B1/ru not_active IP Right Cessation
- 1996-09-20 NZ NZ318712A patent/NZ318712A/xx unknown
- 1996-09-20 PT PT96306850T patent/PT764632E/pt unknown
- 1996-09-20 KR KR1019980701968A patent/KR19990045727A/ko not_active Application Discontinuation
- 1996-09-20 SI SI9630344T patent/SI0764632T1/xx unknown
-
1998
- 1998-03-17 NO NO981204A patent/NO981204L/no not_active Application Discontinuation
-
2001
- 2001-10-22 GR GR20010401833T patent/GR3036963T3/el not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN1202106A (zh) | 1998-12-16 |
DE69614057T2 (de) | 2002-03-14 |
CZ82198A3 (cs) | 1998-07-15 |
BR9610481A (pt) | 1999-05-11 |
EP0764632A2 (de) | 1997-03-26 |
TR199800521T1 (xx) | 1998-06-22 |
EA199800317A1 (ru) | 1998-10-29 |
EP0764632B1 (de) | 2001-07-25 |
NZ318712A (en) | 1999-08-30 |
AU7077096A (en) | 1997-04-09 |
PT764632E (pt) | 2001-12-28 |
NO981204L (no) | 1998-04-17 |
EA001217B1 (ru) | 2000-12-25 |
HUP9802257A2 (hu) | 1999-02-01 |
AU715493B2 (en) | 2000-02-03 |
SI0764632T1 (en) | 2001-12-31 |
PL325865A1 (en) | 1998-08-17 |
EP0764632A3 (de) | 1997-12-10 |
CA2232090A1 (en) | 1997-03-27 |
ES2158996T3 (es) | 2001-09-16 |
MX9802097A (es) | 1998-08-30 |
NO981204D0 (no) | 1998-03-17 |
ATE203511T1 (de) | 2001-08-15 |
GR3036963T3 (en) | 2002-01-31 |
DK0764632T3 (da) | 2001-09-24 |
HUP9802257A3 (en) | 1999-04-28 |
IL123677A0 (en) | 1998-10-30 |
WO1997010822A1 (en) | 1997-03-27 |
JPH11513376A (ja) | 1999-11-16 |
KR19990045727A (ko) | 1999-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9802130A (es) | Agonistas adrenergicos beta3 selectivos. | |
DE69614057T2 (de) | Selektive Beta3-adrenergische Agonisten | |
HUP9700368A2 (hu) | II-típusú diabetes mellitus kezelése amilin agonistákkal | |
DE69939705D1 (de) | Behandlung der pompeschen krankheit | |
DE69616151T2 (de) | Benzimidazolderivate, deren Herstellung und deren therapeutische Anwendung | |
NO305074B1 (no) | Aminosyrederivater, medikamenter inneholdende disse forbindelser og anvendelser derav | |
ATE83659T1 (de) | Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus. | |
DK0790824T3 (da) | 2,2-dichloralkancarboxylsyrer, fremgangsmåde til fremstilling deraf, lægemidler indeholdende disse og anvendelse af disse lægemidler til behandling af insulinresistens | |
MX9708621A (es) | AGONISTAS beta-ADRENERGICOS, COMPOSICIONES QUE LOS CONTIENEN Y USO DE LOS MISMOS. | |
DE69827853D1 (de) | Verwendung von ibudilast zur herstellung eines arzneimittels zur behandlung multiple sklerose | |
KR890011589A (ko) | 벤즈아미드의 용도 | |
ATE79257T1 (de) | Verwendung von tetrahydrobenz(c,d>indol-6carboxamiden zur herstellung von arzneimitteln zur behandlung von angstzustaenden. | |
DE69516110T2 (de) | Verwendung von riluzol zur behandlung mitochondrialer erkrankungen | |
BG102222A (en) | The use of derivatives of the sulphaminic acid, acylsulphanomides or sulphamoylcarbamates for the preparation of a medicament for reducing lipoprotein levels | |
DE68900516D1 (de) | Therapeutische mittel zur behandlung von magengeschwueren. | |
ES2181923T3 (es) | 4-hidroxicumarin-3-carboxamidas para el tratamiento de la diabet es mellitus no dependiente de la insulina. | |
KR910002456A (ko) | 당뇨병 치료용 제약 조성물 | |
ATE212842T1 (de) | Quinoxalin-derivate zur behandlung von tinnitus | |
ATE382367T1 (de) | Behandlung des typ 1 diabetes vor und nach expression von prädispositionsmarkern | |
CA2236269A1 (en) | Selective .beta.3 adrenergic agonists | |
MX9708618A (es) | AGONISTAS beta-ADRENERGICOS, COMPOSICIONES QUE LOS CONTIENEN Y USO DE LOS MISMOS. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |